What is Cour?
Founded in 2015 and headquartered in Evanston, Illinois, Cour is a pioneer in the biotechnology sector, specifically focusing on antigen-specific immune tolerance. The company's core technology is designed to reprogram the immune system, offering a transformative approach to treating complex diseases such as Type 1 Diabetes, Myasthenia Gravis, and Primary Biliary Cholangitis. By moving beyond traditional symptom management, Cour aims to restore immune balance through disease-modifying therapies. Its operational model integrates rigorous research and development with pilot manufacturing, positioning the firm as a critical player in the next generation of precision medicine and pharmaceutical innovation.
How much funding has Cour raised?
Cour has raised a total of $185M across 3 funding rounds:
Unspecified
$30M
Series A
$105M
Series B
$50M
Unspecified (2022): $30M with participation from Alpha Wave Ventures
Series A (2024): $105M led by Lumira Ventures and Alpha Wave Global
Series B (2026): $50M supported by Alpha Wave Global, Roche, Sanofi, Angelini Ventures, JDRF T1D Fund, Pfizer, and Lumira Ventures
Key Investors in Cour
Lumira Ventures
Lumira Ventures is Canada's largest life sciences venture capital firm, specializing in investments in healthcare innovators across various stages, from early-stage to revenue-generating biotech, biotherapeutics, and medical devices.
Alpha Wave Global
Alpha Wave Global focuses on best-in-class venture and growth-stage companies, aiming to be a helpful, long-term partner to founders while seeking uncorrelated return streams.
Roche
Roche is a global pioneer in pharmaceuticals and diagnostics, dedicated to advancing science to improve people's lives through innovative healthcare solutions and personalized medicine.
What's next for Cour?
With the infusion of $50M, Cour is poised to transition into a more advanced phase of clinical validation. The strategic focus will likely center on scaling its pipeline and expanding its manufacturing capabilities to support late-stage trials. Given the participation of major biopharmaceutical players and specialized venture impact funds, the company is strategically aligned to navigate the complexities of regulatory approval and commercialization. Future milestones will likely involve the expansion of its therapeutic reach into additional autoimmune indications, further solidifying its market position as a leader in immune-mediated disease intervention.
See full Cour company page
